Safety of long-term prophylaxis with BAY 94-9027: Interim results of >5 years of treatment in the PROTECT VIII extension trial

被引：0
|
作者：
Reding, Mark T. [1 ]
Ng, Hen Joo [2 ]
Tseneklidou-Stoefer, Despina [3 ]
Linardi, Camila [4 ]
Lalezari, Shadan [5 ,6 ]
机构：
[1] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA
[2] Singapore Gen Hosp, Dept Haematol, Singapore, Singapore
[3] Bayer, Berlin, Germany
[4] Bayer, Whippany, NJ USA
[5] Chaim Sheba Med Ctr, Israel Natl Hemophilia Ctr, Tel Hashomer, Israel
[6] Tel Aviv Univ, Sackler Sch Med, Tel Hashomer, Israel
来源：
HAEMOPHILIA | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
W-P-001 (4
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [1] Effective protection for >5 years with bay 94-9027 prophylaxis: interim results from the protect VIII extension trial
    Thomson, G.
    Holme, P. A.
    Wang, M.
    Enriquez, M. Maas
    [J]. HAEMOPHILIA, 2018, 24 : 114 - 114
  • [2] BAY 94-9027 provides effective long-term prophylaxis in pediatric patients: Interim results of the PROTECT VIII Kids extension study
    Kenet, Gili
    Biss, Tina
    Steele, MacGregor
    Linardi, Camila
    Tseneklidou-Stoeter, Despina
    Saxena, Kapil
    [J]. HAEMOPHILIA, 2018, 24 : 15 - 15
  • [3] BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
    Lalezari, Shadan
    Reding, Mark T.
    Pabinger, Ingrid
    Holme, Pal Andre
    Negrier, Claude
    Chalasani, Pavani
    Shin, Ho-Jin
    Wang, Maria
    Tseneklidou-Stoeter, Despina
    Maas Enriquez, Monika
    [J]. HAEMOPHILIA, 2019, 25 (06) : 1011 - 1019
  • [4] CONFIRMED SAFETY PROFILE OF BAY 94-9027 PROPHYLAXIS FOR ≥5 YEARS: OUTCOMES FROM THE PROTECT VIII AND PROTECT VIII KIDS EXTENSION STUDIES
    Mancuso, M. E.
    Holme, P. A.
    Kenet, G.
    Simpson, M.
    Di Minno, M. N. D.
    Baumann, A.
    Enriquez, Maas M.
    Reding, M. T.
    [J]. HAEMATOLOGICA, 2021, 106 (09) : 7 - 8
  • [5] Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study
    Reding, Mark T.
    Pabinger, Ingrid
    Holme, Pal Andre
    Poulsen, Lone
    Negrier, Claude
    Chalasani, Pavani
    Enriquez, Monika Maas
    Wang, Maria
    Meijer, Karina
    Mancuso, Maria Elisa
    Lalezari, Shadan
    [J]. HAEMOPHILIA, 2021, 27 (03) : E347 - E356
  • [6] BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study
    Ahuja, Sanjay
    Fischer, Kathelijn
    Biss, Tina
    Enriquez, Monika Maas
    Mancuso, Maria-Elisa
    Steele, MacGregor
    Wang, Maria
    Kenet, Gili
    [J]. BLOOD, 2020, 136
  • [7] EFFICACY AND SAFETY OF BAY 94-9027 IS SUSTAINED FOR 5 YEARS: OUTCOMES IN PATIENTS FROM THE PROTECT VIII AND PROTECT VIII KIDS EXTENSION STUDIES
    Santagostino, E.
    Di Minno, M. N. D.
    Lalezari, S.
    Kenet, G.
    Enriquez, M. Maas
    Wang, M.
    Reding, M.
    [J]. HAEMOPHILIA, 2020, 26 : 73 - 73
  • [8] BAY 94-9027 EFFICACY/SAFETY SUSTAINED FOR 5 YEARS: DATA FROM 33 PATIENTS (PROTECT VIII EXTENSION)
    Reding, Mark
    Poulsen, Lone
    Liu, Tian
    Holme, Pal Andre
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66
  • [9] EFFICACY AND SAFETY OF BAY 94-9027 PROPHYLAXIS IS SUSTAINED FOR ≥ 6 YEARS: OUTCOMES IN 22 PATIENTS IN THE PROTECT VIII EXTENSION STUDY
    Mancuso, M. E.
    Klamroth, R.
    Miesbach, W.
    Holme, P. A.
    Enriquez, M. Maas
    Reding, M. T.
    [J]. HAEMOPHILIA, 2021, 27 : 64 - 65
  • [10] Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study
    Reding, Mark T.
    Poulsen, Lone Hvitfeldt
    Tian, Liu
    Holme, Pal Andre
    [J]. BLOOD, 2018, 132
12345